RET and medullary thyroid gland carcinoma: The next-generation molecular tool, Afirma GSC, was released to improve the GEC’s SP and incorporated additional components for BRAFV600E mutation, RET/PTC fusion, parathyroid tissue, and medullary thyroid cancer (MTC) (16).